KR20150023405A - 간 기능 개선 방법 - Google Patents

간 기능 개선 방법 Download PDF

Info

Publication number
KR20150023405A
KR20150023405A KR20147035500A KR20147035500A KR20150023405A KR 20150023405 A KR20150023405 A KR 20150023405A KR 20147035500 A KR20147035500 A KR 20147035500A KR 20147035500 A KR20147035500 A KR 20147035500A KR 20150023405 A KR20150023405 A KR 20150023405A
Authority
KR
South Korea
Prior art keywords
patient
methazolamide
diabetes
liver
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147035500A
Other languages
English (en)
Korean (ko)
Inventor
켄 웰더
가이 크립너
제프 니콜슨
Original Assignee
베바 파마슈티칼스 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베바 파마슈티칼스 엘티디 filed Critical 베바 파마슈티칼스 엘티디
Publication of KR20150023405A publication Critical patent/KR20150023405A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
KR20147035500A 2012-05-24 2013-03-15 간 기능 개선 방법 Withdrawn KR20150023405A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
US201261666574P 2012-06-29 2012-06-29
US61/666,574 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Publications (1)

Publication Number Publication Date
KR20150023405A true KR20150023405A (ko) 2015-03-05

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147035500A Withdrawn KR20150023405A (ko) 2012-05-24 2013-03-15 간 기능 개선 방법

Country Status (15)

Country Link
US (2) US20150150855A1 (https=)
EP (1) EP2854807A4 (https=)
JP (2) JP6360826B2 (https=)
KR (1) KR20150023405A (https=)
CN (2) CN104487073A (https=)
BR (1) BR112014029308A2 (https=)
CA (1) CA2874513A1 (https=)
CO (1) CO7160082A2 (https=)
HK (1) HK1209051A1 (https=)
MX (1) MX362111B (https=)
NZ (2) NZ702645A (https=)
RU (1) RU2653478C2 (https=)
SG (2) SG11201407787VA (https=)
WO (1) WO2013173859A1 (https=)
ZA (1) ZA201408704B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
US20150174108A1 (en) * 2012-05-24 2015-06-25 Vera Pharmaceuticals Ltd Method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
EA010422B1 (ru) 2003-08-01 2008-08-29 Янссен Фармацевтика Н.В. Замещённые индол-о-глюкозиды
PL2106260T3 (pl) * 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
US20150174108A1 (en) * 2012-05-24 2015-06-25 Vera Pharmaceuticals Ltd Method of weight reduction

Also Published As

Publication number Publication date
NZ723206A (en) 2018-02-23
HK1209051A1 (en) 2016-03-24
MX2014014317A (es) 2015-08-10
US20150150855A1 (en) 2015-06-04
CN109498623A (zh) 2019-03-22
RU2653478C2 (ru) 2018-05-08
EP2854807A1 (en) 2015-04-08
EP2854807A4 (en) 2016-03-16
CN104487073A (zh) 2015-04-01
SG10201705388XA (en) 2017-07-28
RU2014152196A (ru) 2016-07-20
WO2013173859A1 (en) 2013-11-28
ZA201408704B (en) 2018-07-25
JP6360826B2 (ja) 2018-07-18
NZ702645A (en) 2016-08-26
JP2015517534A (ja) 2015-06-22
SG11201407787VA (en) 2014-12-30
JP2018090589A (ja) 2018-06-14
CA2874513A1 (en) 2013-11-28
MX362111B (es) 2019-01-07
CO7160082A2 (es) 2015-01-15
US20180333399A1 (en) 2018-11-22
BR112014029308A2 (pt) 2017-06-27
JP6412241B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
CN1960735B (zh) 药物组合在治疗胰岛素抗性中的应用
EP2707017B1 (en) Lixisenatide and metformin for treatment of diabetes type 2
US20120040898A1 (en) Pharmaceutical compositions
US8017633B2 (en) Roflumilast for the treatment of diabetes mellitus
CN101511364A (zh) 用于糖尿病的治疗组合
JP2014527506A (ja) 糖尿病治療のための組み合わせ
CA2543498A1 (en) Use of hydroxylated amino acids for treating diabetes
JP6412241B2 (ja) 肝機能改善法
KR20100135700A (ko) 지방성 간 질환의 치료용 의약 조성물
US20180333398A1 (en) Method of weight reduction
MX2012011517A (es) El uso de diacereina como una terapia adyuvante para diabetes.
AU2016206292B2 (en) A method of improving liver function
WO2017126524A1 (ja) 糖尿病治療剤の併用
HK1165292A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180309

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190207

WITB Written withdrawal of application